QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 发表日期：2016     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China 期刊论文 ONCOTARGET, 2016, 卷号: 7, 期号: 35 作者:  Zhang, Qingyuan;  Shao, Zhimin;  Shen, Kunwei;  Li, Li;  Feng, Jifeng 收藏  |  浏览/下载：64/0  |  提交时间：2019/12/05 advanced breast cancer  fulvestrant  endocrine therapy  hormone receptor-positive breast cancer   Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China 期刊论文 2016, 卷号: 7, 期号: 35, 页码: 57301-57309 作者:  Zhang, Qingyuan;  Shao, Zhimin;  Shen, Kunwei;  Li, Li;  Feng, Jifeng 收藏  |  浏览/下载：59/0  |  提交时间：2020/01/04 advanced breast cancer  fulvestrant  endocrine therapy  hormone receptor-positive breast cancer   Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment. 期刊论文 2016, 卷号: 34, 期号: 15 作者:  Xu, Binghe;  Sun, Tao;  Zhang, Qingyuan;  Yuan, Zhongyu;  Zhang, Pin 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04 Randomized phase III trial of utidelone, a genetically engineered epothilone analog, in combination with capecitabine versus capecitabine alone for metastatic breast cancer patients with previous taxane and anthracycline treatment. 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2016-05-20 作者:  Xu, Binghe;  Sun, Tao;  Zhang, Qingyuan;  Yuan, Zhongyu;  Zhang, Pin 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/04